Literature DB >> 11890697

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice.

Krisztina Monory1, Eleni Th Tzavara, Jinette Lexime, Catherine Ledent, Marc Parmentier, Anna Borsodi, Jacques Hanoune.   

Abstract

In this study we report data suggesting the presence of a non-CB1, non-CB2 cannabinoid site in the cerebellum of CB1-/- mice. We have carried out [(35)S]GTPgammaS binding experiments in striata, hippocampi, and cerebella of CB1-/- and CB1(+/+) mice with Delta(9)-THC, WIN55,212-2, HU-210, SR141716A, and SR144528. In CB1-/- mice Delta(9)-THC and HU-210 did not stimulate [(35)S]GTPgammaS binding. However, WIN55,212-2 was able to stimulate [(35)S]GTPgammaS binding in cerebella of CB1-/- mice. The maximal effect of this stimulation was 31% that of wild type animals. This effect was reversible neither by CB1 nor CB2 receptor antagonists. Similar results were obtained with the endogenous cannabinoid, anandamide. However, adenylyl cyclase was not inhibited by WIN55,212-2 or anandamide in the CB1(minus sign/minus sign) animals. In striata and hippocampi of CB1-/- mice no [(35)S]GTPgammaS stimulation curve could be obtained with WIN55,212. Our findings suggest that there is a non-CB1 non-CB2 receptor present in the cerebellum of CB1-/- mice. (C)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11890697     DOI: 10.1006/bbrc.2002.6635

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.

Authors:  Alexander F Hoffman; Alice M Macgill; Dennison Smith; Murat Oz; Carl R Lupica
Journal:  Eur J Neurosci       Date:  2005-11       Impact factor: 3.386

4.  The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.

Authors:  Anne B Need; Richard J Davis; Jesline T Alexander-Chacko; Brian Eastwood; Eyassu Chernet; Lee A Phebus; Dana K Sindelar; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-11-18       Impact factor: 4.530

5.  The orphan receptor GPR55 is a novel cannabinoid receptor.

Authors:  E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 6.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 7.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 8.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

9.  Alkylindole-sensitive receptors modulate microglial cell migration and proliferation.

Authors:  Susan Fung; Allison E Cherry; Cong Xu; Nephi Stella
Journal:  Glia       Date:  2015-04-27       Impact factor: 7.452

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.